• All News
• Consumer
• Pro
• New Drugs
• Pipeline
• Clinical Trials
• FDA Alerts

Andexanet Yields Better Control of Hematoma Expansion Than Usual Care

Medically reviewed by Carmen Pope, BPharm. Last updated on May 17, 2024.

By Elana Gotkine HealthDay Reporter

FRIDAY, May 17, 2024 -- For patients who had taken factor Xa inhibitors within 15 hours before having an acute intracerebral hemorrhage, andexanet alfa, which reverses the effects of factor Xa inhibitors, results in better control of hematoma expansion than usual care, according to a study published in the May 16/23 issue of the New England Journal of Medicine.

Stuart J. Connolly, M.D., from McMaster University in Hamilton, Ontario, Canada, and colleagues randomly assigned patients who had taken factor Xa inhibitors within 15 hours before having an acute intracerebral hemorrhage to receive andexanet or usual care in a 1:1 ratio (263 and 267 patients, respectively). Efficacy was assessed in an interim analysis involving 452 patients, while safety was assessed in all 530 patients.

The most common indication for factor Xa inhibitors was atrial fibrillation. The researchers found that hemostatic efficacy was achieved in 67.0 and 53.1 percent of 224 and 228 patients receiving andexanet and usual care, respectively (adjusted difference, 13.4 percentage points). The median reduction from baseline to the one- to two-hour nadir in anti-factor Xa activity was 94.5 and 26.9 percent with andexanet and usual care, respectively. Overall, 10.3 and 5.6 percent of patients receiving andexanet and usual care had thrombotic events, respectively; ischemic stroke occurred in 6.5 and 1.5 percent, respectively. No appreciable between-group differences were seen in the modified Rankin scale score or in death within 30 days.

"The reduction in hematoma expansion with andexanet as compared with usual care was accompanied by an increase in thrombotic events, including stroke," the authors write.

The study was funded by Alexion AstraZeneca Rare Disease, AstraZeneca Biopharmaceuticals, and, previously, Portola and Alexion Pharmaceuticals.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted May 2024

More news resources

• FDA Medwatch Drug Alerts
• Daily MedNews
• News for Health Professionals
• New Drug Approvals
• New Drug Applications
• Drug Shortages
• Clinical Trial Results
• Generic Drug Approvals

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.